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Abstract
Purpose of Review The pathogenesis of DILI is currently un-
known; however, research has shown strong genetic associa-
tions with some DILIs. This paper describes the variant alleles
uncovered by GWAS and discusses their potential role as sus-
ceptibility biomarkers.
Recent Findings An association with HLADRB1*15:01 and
amoxicillin/clavulanate DILI has been shown by a number of
research groups. The presence of the HLA-B*57:01 allele has
been associated with an 81-fold increased risk of flucloxacillin
DILI. The HLA-B*35:02 allele has significant association
with minocycline DILI.
Summary With the exception of abacavir for HIV therapy, no
other prospective genetic screening tests have met the thresh-
old for clinical application. This is largely because DILI inci-
dence is too low to warrant the cost and effort associated with
testing. Perhaps, with the development of personalised medi-
cine, a panel of genes for disease susceptibility, drug efficacy
and adverse reactions could be tested once off. This would
change the cost-effectiveness paradigm, personalise
healthcare and reduce DILI risk by avoiding medications in
patients with specific HLA alleles.
Keywords Drug-induced liver injury . Genetic association .
Biomarker . Predisposition: Amoxicillin/clavulanate .
Flucloxacillin
Drug-induced liver injury (DILI) is the leading cause of acute
liver failure in the UK and USA [1, 2]. It accounts for approx-
imately 50% of all cases and is associated with high morbidity
and mortality. One study found that patients with DILI-
associated jaundice had an 11.7% chance of progressing to
fulminant hepatic failure resulting in either death or transplan-
tation [3]. Although, paradoxically, this condition is rare, oc-
curring in only 1 in every 10,000 patients receiving DILI-
associated drugs, these medications are used frequently in
clinical practice [4]; therefore, healthcare impacts on patient
safety and cost are significant, over and above this most DILI
does not cause overt liver failure but leads to patient morbidity
and consumption of health care resource.
DILI arises from an interplay between pharmacodynamic
drug properties acting with specific genetic/non-genetic host
factors; reactions which are not predictable from drug dosing.
The idiosyncratic and diverse disease presentation in DILI
makes research challenging as the mechanistic understanding
of this condition is still limited [5]. DILI is typically a clinical
diagnosis of exclusion and management includes prompt ces-
sation of the offending drug with supportive and symptomatic
care [6]. Limitations in DILI prediction, diagnosis and clinical
outcome have driven the growing interest for the development
of new specific and sensitive biomarkers.
Although genetic factors have been associated with DILI
since the 1980s, the development of genome-wide association
studies (GWAS) has enabled the detection and confirmation of
specific genetic risk factors [4]. Using this technique, a num-
ber of genetic links with DILI have been revealed. The data
from these studies may provide support for the use of genetic
variants as a biomarker for susceptibility to DILI for a given
medication. This type of test would be classed as a suscepti-
bility or risk biomarker. Before the clinical implementation of
such screening, a biomarker must be qualified. A framework
for this already exists.
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In general terms, stages in biomarker development include
the discovery of association, validation for its intended context
of use and optimization for population use and clinical appli-
cation [7]. The association between genetic factors and DILI
have existed for decades; this addresses the first stage in bio-
marker development of initial discovery. With regard to the
secondary stage validation, there are a select number of med-
ications with various studies to support their genetic associa-
tion with DILI [8–10]. This research continues for various
other DILI-related drugs. The next step is to investigate the
benefit of prospective pharmacogenetic testing in clinical
situations to optimise drug choice or patient management.
The study design may follow a similar structure to that of
PREDICT-1, a first of its kind trial (discussed below) [11].
Once a marker and its method of analysis have gone
through biological and technical development, the clinical
effectiveness of its use must be assessed [7]. The regulato-
ry body will require a biomarker to show clinical validity,
utility, cost-effectiveness and safety before it can be used
in medical practice [12].
Using HIV therapy as an exemplar, patients with the hu-
man leukocyte antigen (HLA)B*5701 allele are at an increased
risk of developing a hypersensitivity reaction to the nucleoside
reverse transcriptase inhibitor abacavir [13]. Trials were de-
veloped to validate the use of the HLA-B*5701 allele as a
biomarker for abacavir hypersensitivity. Following on from
this, PREDICT-1 was the first fully powered, randomised
and double-blinded study designed to determine the effective-
ness of prospective pharmacogenetic screening of HLA-
B*5701 in preventing hypersensitivity reactions [11]. The re-
sults showed that prospective HLA-B*5701 testing reduced
hypersensitivity reactions from 2.7% in the control group to
0% in the prescreened group. Research has proven that this
screening test is cost effective [14]. One reason for this is the
high positive predictive value of the test [15, 16]. The design
of this trial may have utility in exploring the benefits of pro-
spective pharmacogenetics testing for other key pharmacolog-
ical agents with unfavourable and costly side effects such as
those associated with DILI. This being said, the low positive
predictive value of genetic associations in DILI, which will be
discussed in the following sections, make prospective genetic
testing less likely to be cost effective.
Amoxicillin and Clavulanate-Associated DILI
Amoxicillin/clavulanate is the single most common causal
agent of idiosyncratic DILI reported in registries, 10–13% of
DILI-related hospitalisations [8, 17]. Amoxicillin is a com-
monly used antimicrobial which treats a variety of infections
and has a relatively low side effect profile. The incidence of
DILI with this agent alone is 0.3 per 10,000 prescriptions,
much lower than the reports from amoxillicin/clavulanate
use which is quantified as 1.7 per 10,000 prescriptions [18,
19]. The injury is thought to be from clavulanate, it is idiosyn-
cratic but increases with age, repeated exposure, male sex and
longer duration of treatment [18, 19]. The pattern of damage is
variable. A predominantly hepatocellular injury tends to occur
in younger individuals with shorter durations of treatment
whilst cholestatic and mixed damage, the most common form,
occurs more frequently in older patients with longer treatment
regimens [20, 21].
The HLA genetic association between amoxicillin/
clavulanate and DILI was first established by Hautekeete
et al. in 1999. This group reported that the frequency of a
HLA haplotype specifically antigen–D Related (DR)
DRB1*15:01-DRB5*01:01-DQB1*06:02 was significantly
increased in a European population of patients with
amoxicillin/clavulanate-induced DILI compared to control
subjects (57.1% compared to 11.1%) [22]. This association
between HLADRB1*15:01 and amoxicillin/clavulanate-
induced DILI has been replicated by a number of studies,
[22, 23]. Donaldson et al. conducted a large national study
and found the frequency of DRB11501 in DILI patients was
significantly higher than the population control: 53 and 30%,
respectively [8]. The study also enrolled a ‘treatment control’
group of patients who had been exposed to amoxicillin/
clavulanate with no reported side effects.Within this treatment
control group, 30% of patients had DRB11501. This high-
lights the complex nature of genetic studies; not all patients
with the gene or single nucleotide polymorphism develop the
disease and conversely not all patients with the disease have
the associated genetics. One study in a Spanish cohort failed to
replicate this association [24].
A study which followed on from this identified two novel
genetic factors associated with amoxicillin/clavulunate-
induced DILI: HLA-A*02:01 [odds ratio 2.2 (95% CI 1.6–
3.2)] in all patients and HLA-B*18:01 [odds ratio 4.0 (95%
CI 1.5–11)] in Spanish patients alone. These results suggest
that this reaction which is associated with MHC class I mol-
ecules may be dependent on ethnicity. A similar finding was
reported regarding to HLA-B*15:02 and carbamazepine-
induced severe skin reactions as this association was only
applicable in certain Asian cohorts [25].
One study has linked specific haplotypes with specific clin-
ical forms of DILI, cholestatic DILI has been associated with
the DRB11501/DQB10602 haplotype whilst A3002/HLA
B1801 is has been linked with hepatocellular DILI [26].
Another study has highlighted that patients who have
double-null heterozygosity for glutathione S-transferase
(GSTT1/GSTM1), an enzyme which detoxifies electrophilic
compounds, are at an increased risk of amoxicillin/
clavulanate-induced DILI [27].
In 2011, Lucena et al. conducted the most powerful and
comprehensive study into the genetic risk factors associated
with amoxicillin/clavulanate DILI. This was achieved through
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GWAS which looked at a large number of single nucleotide
polymorphismmarkers from 201 Caucasian European and US
patients with amoxicillin/clavulanate DILI. A large number of
control patients, 532, were matched for genetic background.
The results from this study not only confirmed the previous
associations of HLA DRB1*15:01 and DQB1*0602 with
amoxicillin/clavulanate DILI but also identified additional
HLA risk factors with an apparent statistical interaction be-
tween two HLA alleles. High resolution HLA genotyping
with 177 cases and 219 controls confirmed associations of
HLA-A*0201 (P = 2 × 10−6) and HLA-DQB1*0602
(P = 5 × 10–6) and their interaction (P = 0.005) [28].
Additional population dependant effects were observed in
HLA alleles with minimal significance.
Assuming the prevalence of amoxicillin/clavulanate-
associated DILI is 0.014%, the best positive predictive value
generated from this study is 0.1% for Northwestern Europeans
based on the presence of both A*0201 and DQB1*0602 (with
a frequency of 41% in cases). This value of 0.1% signifies that
HLA genotyping will not be an effective method to prospec-
tively identify those patients at risk of amoxicillin/clavulanate
DILI; however, the data suggests that HLA genotyping may
be of value in strengthening the diagnosis of amoxicillin/
clavulanate DILI in view of the high negative predictive
values noted. Based on the absence of A*0201 in
Northwestern Europeans (74% carriage frequency in cases),
the best negative predicative value is 0.006%. This value was
0.007% for the Spanish cohort based on the absence of
rs2523822/C (74% carriage frequency in cases) [28].
This study has demonstrated that both class I and II HLA
genotypes have a role in amoxicillin/clavulanate DILI suscep-
tibility, thus indicating the significance of the adaptive im-
mune response in the pathogenesis of DILI. Although the
HLA genotypes which have been identified may be useful
for future studies into the pathogenesis of DILI, their low
positive predictive value suggests they have limited utility as
a predictive biomarker of amoxicillin/clavulanate DILI; how-
ever, their high negative predictive value may have a role in
DILI diagnosis.
Although the precise pathophysiological mechanisms un-
derlying the phenotype-genotype association in amoxicillin/
clavulanate-induced DILI is still unknown, it is thought to be
immunological due to specific HLA subtype involvement.
HLA-DR is a major histocompatibility complex (MHC)
class II cell surface receptor which is encoded by the HLA
complex on a section of chromosome 6. These HLA-DR re-
ceptor and its ligand, which are typically a peptide consisting
of nine amino acids or more, constitutes a ligand for T cell
receptors. It is thought that either drug or drug-class specific
factors have a role in the initiating event of DILI which con-
stitutes the reactive metabolite covalently binding to a protein
to form an adduct. The antigen-presenting cells process this
hapten; it undergoes cleavage to form peptide fragments
which are presented to T cells through MHC class I or II
molecules and co-stimulatory signals. This, together with the
properties of the cytokine micro-environment within the liver,
determines both the nature and magnitude of the DILI re-
sponse [4].
The average onset of symptoms from first starting
amoxicillin/clavulanate is 18 days. In these patients, there is
often the presence of features associated with hypersensitivity
including rash, fever and eosinophilia. The majority of pa-
tients make a full recovery within 4–6 months; however, there
are a select few patients who go on to develop fulminant
hepatic failure and require transplantation. Fortunately, this
is rare.
Research has not decisively established that these ‘risk al-
leles’ are truly causative of DILI; studies have merely reported
very strong associations between them both. There is a need to
understand the pathophysiology of amoxicillin/clavulanate
DILI in order to explain why only a small proportion of pa-
tients with these specific genetic variations develop this com-
plication, to avoid denying this important antimicrobial to a
large number of patients. Further studies into these areas of
uncertainty and the direct role of the immune system in DILI
are required before elucidating the impact of genetic screening
prior to amoxicillin/clavulanate treatment.
Flucloxacillin-Associated DILI
Flucloxacillin is used for the treatment of staphylococcal in-
fections and has been shown to precipitate, typically the cho-
lestatic form, of DILI. In the UK, flucloxacillin is the second
commonest cause of drug-induced jaundice [17] despite the
incidence of flucloxacillin DILI being low, reported as 8.5
cases per 100,000 new users [29]. Flucloxacillin accounts
for 16% of all DILI cases in Sweden, where it is the most
common cause of idiosyncratic liver disease [30].
A seminal GWAS study which analysed 51 patients with
flucloxacillin-induced DILI reported a strong association with
HLA-B*57:01 (OR = 80.6; 95% CI = 22.8–284.9); the pres-
ence of this allele was associated with an 81-fold increased
risk of DILI secondary to flucloxacillin. In a replication co-
hort, this association was still significant with the results sug-
gesting that if an individual tested positive for HLAB*57:01,
they would have a 100-fold increased risk of developing DILI
with flucloxacillin use [31, 32]. The absolute risk for this
reaction was calculated as 1:500–1:1000. This discovery is
particularly interesting as it is the same HLA allele which is
associated with abacavir sensitivity, as previously discussed,
where hepatic injury is not a typical feature. The underlying
pathogenesis of flucloxacillin-induced DILI has been de-
scribed by Monshi et al. [31]. Flucloxacillin has been shown
to covalently bind to select lysine residues on circulating al-
bumin, the degree of binding controls, the intensity of the T
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cell proliferative response and subsequent immune reaction.
In addition, flucloxacillin-specific mononuclear cell responses
were found in peripheral blood samples taken from individ-
uals with a history of DILI. One study characterised
flucloxacillin reactive CD4+ and CD8+ T cell clones from
samples from these individuals, whilst another study has
shown flucloxacillin’s ability to activate naïve CD8+ T cells
from HLA-B*5701 positive volunteers [33].
With regards to pretreatment testing of HLAB* 57:01, the
sensitivity and specificity was high at 87 and 94%, respective-
ly. However, due to the low incidence of flucloxacillin asso-
ciated DILI, the positive predictive value of the test would be a
mere 0.12%. In translating these figures to clinical practice,
more than 13,500 patients would need to be tested before 1
case of flucloxacillin DILI could be avoided [34]. Also, in
doing this many patients who test HLAB* 57:01 positive
who would not have developed DILI with flucloxacillin
would be denied this effective therapy. It was therefore
thought that isolated routine HLAB* 57:01 screening prior to
flucloxacillin use would be neither economically nor clinically
viable for DILI prevention.
Minocycline-Associated DILI
Minocycline is a semi-synthetic tetracycline derivative and
bacteriostatic antibiotic. It is mainly effective against
coagulase-negative staphylococci and Propionibacterium
acnes; it’s most common indication is in the treatment of
acne vulgaris [35]. For this indication, minocycline is giv-
en for a prolonged period, this can be months to years,
and the treatment cohort is typically young patients who
are otherwise healthy.
Gough et al. described the association between minocycline
and DILI in 1996 after investigating a number of cases which
had reported to the Committee on Safety of Medicines [36].
Since then, a number of patient studies have supported this
association [37–39]. This research also reports characteristic
clinical features such as systemic arthralgia and detectable
autoantibodies particularly in young women [37].
Urban et al. conducted a GWAS study in 25 Caucasian
patients with minocycline-associated DILI comparing their
genotype to an unexposed population control. Within the
DILI patient cohort, 80% were female, the median age was
19 years and median latency from minocycline initiation and
DILI onset was 318 days. The indication for minocycline use
in all cases was dermatological. This study reported a signif-
icant association between HLA-B*35:02 and risk of
minocycline-DILI with a 16% carrier frequency in DILI cases
compared with a 0.6% in the population control (odds ratio
29.6, 95% CI: 7.8–89.8, p = 2.5 × 10−8). The GWAS results
were confirmed with sequence-based HLA typing. Studies
using in silico modelling techniques have supported the
hypothesis that the direct binding of minocycline to this novel
HLA allele may have an important role in the initiation of
minocycline-DILI [40•]. The authors propose a number of
theories regarding the mechanism of minocycline-induced liv-
er injury; however, the link between HLA-B*35:02 and
minocycline is still unclear.
Within the general population the HLA-B*35:02 allele has
a low frequency of only 0.3% in Caucasians and less than
0.1% in African Americans. Given that the incidence of
minocycline-associated DILI is so low, pre-treatment HLA
typing is unlikely to prevent this condition. However,
genotyping for HLA-B*35:02 may be helpful as a diagnostic
aid in patients with a suspected minocycline-associated DILI
to distinguish it from autoimmune hepatitis.
Other Examples of Genetic Associations and DILI
A number of other studies have identified genetic risk factors
linking specific drugs to DILI. Both HLA-DR and HLA-DQ
genotypes were found to be predictive for DILI induced by
lumiracoxib (HLA-DRB1*1501-HLA-DQB1*0602-HLA-
DRB5*0101-HLA-DQA1*0102, most significant allele
P = 6.8 × 10–25 allelic, odds ratio = 5.0, 95% CI 3.6–7.0)
[9]. This selective cyclooxygenase-2 inhibitor has been re-
cently removed from the market due to hepatotoxicity [9,
10]. Carriers of the HLA allele DQA*02:01 have been asso-
ciated with lapatinib-induced DILI, a tyrosine kinase inhibitor
used in the treatment of breast cancer. (P < .001, odds ra-
tio = 9.0, 95% CI 3.2–27.4) [41]. An overview of the most
important HLA associations uncovered by GWAS is present-
ed in Table 1.
The most recent research conducted by the international
DILI Consortium was a GWAS looking into genetic risk fac-
tors for DILI caused by licenced drugs which do not have any
previously reported genetic associations. GWAS was per-
formed on 862 patients with DILI and 10,588 population
matched controls. All patients were of European ancestry,
and their DILI was associated with one particular drug, pa-
tients with amoxicillin/clavulanate or flucloxacillin DILI were
not included in this study. DILI was associated with the single
nucleotide polymorphism (SNP) rs114577328 (a proxy for
A*33:01, a HLA class 1 allele; odds ratio [OR] 2.7 with a
95% confidence interval [CI] of 1.9–3.8, P = 2.4 × 10−8)
[42•]. Terbinafine, fenofibrate and ticlopidine-related DILI
was shown to have an association with this A*33:01 geno-
type. Interestingly, this novel class 1 allele is relatively rare
amongst the general population. Further phenotypical
analysis indicated that A*33:01-associated DILI was typ-
ically a cholestatic or mixed form of DILI, not hepato-
cellular. Another genetic association made through this
GWAS study was the SNP rs72631567 on chromosome
2 (OR 2, 95% CI of 1.6–2.5, P = 9.7 × 10−9) [42•]. This
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variant was present in a number of patients with DILI
from a variety of drugs and gave a range of cholestatic,
mixed and hepatocellular forms of DILI.
Again, as with the other HLA associations and DILI, the
overall sensitivity and specificity of the A*33:01 allele as a
predictor of this adverse reaction is low. However, this asso-
ciation may be significant in the future treatment of patients
with DILI associated with the A*33:01 allele.
Conclusion
In order to determine the benefit of a pretreatment genetic
screening test and therefore whether there is scope for it in
clinical practice, it is useful to quantify the change in the
incidence of DILI in a given proportion of people with the
associated genetic susceptibility marker. The attributable pro-
portion (AP) can be used to calculate this and has been report-
ed in a select number of the current studies such as the
amoxicillin/clavulanate study by Donaldson et al. . [8]. This
value represents the proportion of disease-cases attributable to
the biomarker and is based on the sensitivity of the laboratory
testing as well as the relative risk of association between the
biomarker and disease established from case control, cohort
studies or by clinical trial. This type of analysis would be
useful in this setting given the complex nature of genetic stud-
ies; not all patients with the gene or single nucleotide poly-
morphism develop the disease and conversely not all patients
with the disease have the associated genetics. Although this
point implies that not everyone who will suffer DILI will be
revealed through the use of this biomarker, it is important to
focus on improving the outcome for the patients who are
highlighted through the screening since this is what the re-
search has shown- their increased susceptibility.
With the exception of abacavir, there is currently no other
prospective genetic screening tests which have met the thresh-
old for clinical application; generally, the incidence of DILI is
too low to warrant the cost and effort associated with screen-
ing. However with the development of the concept of
personalised medicine, potentially, a large panel of genes for
disease susceptibility, drug efficacy and adverse drug reac-
tions could be check once in a lifetime, thereby completely
changing the cost-effectiveness paradigm. This panel of genes
could allow medical professionals to make personalised drug
and treatment choices and, with reference to this paper, to
highlight which medications should be avoided in patients
with specific HLA alleles to reduce the risk of DILI.
Although the research does not support the use of genetic
testing for prevention of DILI, there is evidence to support its
use in diagnosis. The majority of HLA alleles associated with
DILI have a high negative predictive value (NPV). An exam-
ple of this, which has been previously mentioned, is in Lucena
et al.’s study in 2011 on amoxicillin/clavulanate DILI. The
researchers reported the best NPV, expressed as 1-NPV, in
two different ethnic cohorts as 0.006 and 0.007% based on
the absence of A*0201 and rs2523822/C, respectively [28].
Genotyping could therefore be used to rule out adverse hepatic
reactions in patients on particular drugs thus allowing the
consideration of alternative diagnoses. The reliability of
the negative predictive value of genetic testing can also
be used to identify the correct medication underlying the
DILI in a situation where the patient has been exposed to
two concomitant drugs.
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Table 1 Overview of HLA associations with DILI
Drug HLA Allele Type of study Approximate odds ratio Reference(s)
Amoxicillin-clavulanate DRB1*15:01 GWAS and candidate gene 3
DQB1*06:02 [22, 23, 28]
A*02:01 2.2
B*18:01 4.0
Flucloxacillin B*57:01 GWAS 80 [31, 32]
Minocycline B*35:02 GWAS 29.6 [40•]
Lumiracoxib DRB1*15:01 GWAS 5 [9]
DQB1*06:02
Lapatinib DQA*02:01 GWAS and candidate gene 9 [41]
Ximelagatran DRB1*07:01 GWAS Not available (P = 6.0 × 10−6) [43]
DQA1*02:01
Ticlopidine A*33:03 Candidate gene 13 [44]
GWAS genome-wide association studies
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